Axsome Therapeutics, Inc. (AXSM)
| Market Cap | 5.36B |
| Revenue (ttm) | 432.16M |
| Net Income (ttm) | -278.27M |
| Shares Out | 49.24M |
| EPS (ttm) | -5.77 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 608,544 |
| Open | 110.15 |
| Previous Close | 110.86 |
| Day's Range | 108.44 - 112.05 |
| 52-Week Range | 64.11 - 139.13 |
| Beta | 0.45 |
| Analysts | Strong Buy |
| Price Target | 170.20 (+56.35%) |
| Earnings Date | May 5, 2025 |
About AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 ago... [Read more]
Financial Performance
In 2024, Axsome Therapeutics's revenue was $385.69 million, an increase of 42.53% compared to the previous year's $270.60 million. Losses were -$287.22 million, 20.1% more than in 2023.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for AXSM stock is "Strong Buy." The 12-month stock price forecast is $170.2, which is an increase of 56.35% from the latest price.
News
Axsome Therapeutics Q1: Marketing-Driven Growth Masks Profitability Concerns
Axsome Therapeutics reported strong Q1 2025 earnings, with revenue and EPS beats driven by Auvelity and Sunosi, despite high SG&A expenses and net loss. Auvelity shows promising growth in the competit...
Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Piz...
Axsome Therapeutics Clocks Around 60% Topline Growth In Q1
Axsome Therapeutics Inc AXSM on Monday reported first-quarter 2025 revenues of $121.5 million, up from $75 million a year ago, beating the consensus of $119.87 million.
Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Total 1Q 2025 net product revenue of $121.5 million, representing 62% year-over-year growth AUVELITY ® 1Q 2025 net product sales of $96.2 million, representing 80% year-over-year growth SUNOSI ® 1Q 20...
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ann...
Axsome Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today a...
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today a...
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting
Late-breaking oral presentation of results from the positive pivotal ACCORD-2 Phase 3 trial of AXS-05 in Alzheimer's disease agitation
Axsome's depression treatment fails to meet main goal of late-stage study
Axsome Therapeutics said on Tuesday its experimental drug to treat major depressive disorder failed to meet the main goal of a late-stage study.
Axsome Therapeutics' ADHD drug meets main goal in late-stage study
Axsome Therapeutics said on Tuesday its experimental drug to treat attention deficit hyperactivity disorder (ADHD) met the main goal in a late-stage study.
Axsome: The Alzheimer's Agitation Program For AXS-05
Axsome's AXS-05 shows strong efficacy in treating Alzheimer's Disease Agitation, with significant CMAI score reductions in multiple Phase 3 trials. The FDA has greenlit Axsome to submit an sNDA for AX...
Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs
On Monday, Axsome Therapeutics, Inc. AXSM announced that the EMERGE Phase 3 trial of Symbravo (MoSEIC meloxicam and rizatriptan) in patients experiencing inadequate response to oral CGRP inhibitors (m...
Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering
Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering
Axsome Therapeutics, Inc. (AXSM) Q4 2024 Earnings Call Transcript
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2024 Earnings Conference Call February 18, 2025 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - Chief ...
Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade
Axsome Therapeutics, Inc.'s stock has surged over 30% since my last “Hold” rating, driven by key catalysts like the litigation settlement with Teva Pharmaceuticals, announced today. Axsome's Auvelity ...
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'
On Monday, Axsome Therapeutics, Inc. AXSM signed a settlement agreement with Teva Pharmaceuticals Inc TEVA.
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will hos...
US FDA approves Axsome Therapeutics' migraine drug
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
A single oral dose of SYMBRAVO provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours
Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results
Axsome Therapeutics shows strong revenue growth from Auvelity and Sunosi, with promising late-stage pipeline drugs for migraine, fibromyalgia, and narcolepsy. Late-stage pipeline milestones include AX...
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
On Monday, Axsome Therapeutics, Inc. AXSM released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 (dextromethorphan-bupropion) in Alzheimer's disease agitation.
Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling more than 50 points on Monday.
Axsome's drug for Alzheimer's disease agitation meets main goal in late-stage study
Axsome Therapeutics said on Monday its experimental treatment for the Alzheimer's disease-related agitation met the main goal of a late-stage trial.
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer's Disease Agitation
ACCORD-2 Phase 3 trial in Alzheimer's disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse)
Axsome: Focus On AXS-12 Targeting Narcolepsy, Which Just Released Positive Data
Axsome's AXS-12 met its primary endpoint in a Phase 3 study, significantly reducing cataplexy attacks in narcolepsy patients, positioning it for an NDA submission. The narcolepsy market is substantial...